カルナバイオサイエンスの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2021/03/03 | 1,371 | 1,386 | 1,356 | 1,357 | -29 | -2.1% | 39,400 |
2021/03/02 | 1,417 | 1,431 | 1,362 | 1,386 | -38 | -2.7% | 89,300 |
2021/03/01 | 1,417 | 1,452 | 1,402 | 1,424 | +13 | +0.9% | 49,200 |
2021/02/26 | 1,420 | 1,434 | 1,401 | 1,411 | -47 | -3.2% | 56,400 |
2021/02/25 | 1,442 | 1,461 | 1,421 | 1,458 | +20 | +1.4% | 59,000 |
2021/02/24 | 1,468 | 1,477 | 1,430 | 1,438 | -43 | -2.9% | 83,400 |
2021/02/22 | 1,435 | 1,493 | 1,435 | 1,481 | +65 | +4.6% | 104,300 |
2021/02/19 | 1,415 | 1,442 | 1,392 | 1,416 | -23 | -1.6% | 89,900 |
2021/02/18 | 1,421 | 1,455 | 1,410 | 1,439 | +3 | +0.2% | 91,600 |
2021/02/17 | 1,340 | 1,445 | 1,338 | 1,436 | +79 | +5.8% | 146,600 |
2021/02/16 | 1,418 | 1,418 | 1,356 | 1,357 | -65 | -4.6% | 149,800 |
2021/02/15 | 1,435 | 1,449 | 1,388 | 1,422 | -112 | -7.3% | 237,100 |
2021/02/12 | 1,549 | 1,556 | 1,530 | 1,534 | -39 | -2.5% | 86,600 |
2021/02/10 | 1,501 | 1,573 | 1,496 | 1,573 | +53 | +3.5% | 108,600 |
2021/02/09 | 1,551 | 1,551 | 1,494 | 1,520 | -23 | -1.5% | 155,900 |
2021/02/08 | 1,547 | 1,593 | 1,523 | 1,543 | +34 | +2.3% | 288,300 |
2021/02/05 | 1,420 | 1,516 | 1,420 | 1,509 | +81 | +5.7% | 223,500 |
2021/02/04 | 1,433 | 1,452 | 1,418 | 1,428 | -5 | -0.3% | 56,300 |
2021/02/03 | 1,392 | 1,462 | 1,392 | 1,433 | +45 | +3.2% | 177,000 |
2021/02/02 | 1,349 | 1,400 | 1,337 | 1,388 | +37 | +2.7% | 119,500 |
2021/02/01 | 1,319 | 1,352 | 1,301 | 1,351 | +20 | +1.5% | 52,500 |
2021/01/29 | 1,363 | 1,381 | 1,324 | 1,331 | -39 | -2.8% | 93,700 |
2021/01/28 | 1,321 | 1,375 | 1,321 | 1,370 | +8 | +0.6% | 62,300 |
2021/01/27 | 1,329 | 1,362 | 1,322 | 1,362 | +27 | +2% | 49,500 |
2021/01/26 | 1,379 | 1,379 | 1,335 | 1,335 | -43 | -3.1% | 68,700 |
2021/01/25 | 1,350 | 1,382 | 1,333 | 1,378 | +31 | +2.3% | 67,700 |
2021/01/22 | 1,363 | 1,374 | 1,341 | 1,347 | -16 | -1.2% | 63,400 |
2021/01/21 | 1,350 | 1,364 | 1,325 | 1,363 | +22 | +1.6% | 91,200 |
2021/01/20 | 1,310 | 1,351 | 1,298 | 1,341 | +36 | +2.8% | 119,500 |
2021/01/19 | 1,280 | 1,308 | 1,270 | 1,305 | +40 | +3.2% | 64,400 |
2021/01/18 | 1,313 | 1,313 | 1,256 | 1,265 | -41 | -3.1% | 87,700 |
2021/01/15 | 1,236 | 1,310 | 1,234 | 1,306 | +67 | +5.4% | 170,600 |
2021/01/14 | 1,235 | 1,246 | 1,230 | 1,239 | -2 | -0.2% | 59,300 |
2021/01/13 | 1,233 | 1,245 | 1,225 | 1,241 | -5 | -0.4% | 33,300 |
2021/01/12 | 1,231 | 1,246 | 1,216 | 1,246 | +11 | +0.9% | 56,800 |
2021/01/08 | 1,210 | 1,235 | 1,205 | 1,235 | +36 | +3% | 111,200 |
2021/01/07 | 1,195 | 1,211 | 1,195 | 1,199 | +5 | +0.4% | 44,700 |
2021/01/06 | 1,159 | 1,197 | 1,154 | 1,194 | +35 | +3% | 73,700 |
2021/01/05 | 1,160 | 1,169 | 1,150 | 1,159 | -3 | -0.3% | 68,500 |
2021/01/04 | 1,218 | 1,222 | 1,151 | 1,162 | -50 | -4.1% | 158,100 |
2020/12/30 | 1,200 | 1,218 | 1,194 | 1,212 | +5 | +0.4% | 69,300 |
2020/12/29 | 1,171 | 1,212 | 1,171 | 1,207 | +45 | +3.9% | 102,900 |
2020/12/28 | 1,180 | 1,190 | 1,148 | 1,162 | -11 | -0.9% | 84,000 |
2020/12/25 | 1,175 | 1,195 | 1,163 | 1,173 | -2 | -0.2% | 99,900 |
2020/12/24 | 1,140 | 1,182 | 1,132 | 1,175 | +43 | +3.8% | 125,900 |
2020/12/23 | 1,134 | 1,151 | 1,123 | 1,132 | -16 | -1.4% | 125,500 |
2020/12/22 | 1,200 | 1,200 | 1,127 | 1,148 | -55 | -4.6% | 266,900 |
2020/12/21 | 1,210 | 1,225 | 1,180 | 1,203 | -10 | -0.8% | 154,400 |
2020/12/18 | 1,217 | 1,238 | 1,210 | 1,213 | -10 | -0.8% | 128,700 |
2020/12/17 | 1,242 | 1,249 | 1,213 | 1,223 | -23 | -1.8% | 119,000 |
901~
950
件表示中 / 3572件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
カルナバイオ | 30,400円 | -43.1% | - | 0.00% | - | 1.81倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
カイオム | 9,900円 | +2.6% | - | 0.00% | - | 5.73倍 |
|
独自の抗体作製技術を持つ理研発の創薬ベンチャー。医薬品候補抗体導出と技術供与が収益源 |
VIS | 91,000円 | +87.8% | +265.7% | 0.00% | 54.65倍 | 2.51倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
クリングル | 82,300円 | +14.5% | - | 0.00% | - | 2.43倍 |
|
細胞の増殖、保護、修復などの機能があるHGFタンパク質を用いて、難治性疾患治療薬を開発 |
DELTA-P | 65,800円 | - | - | 0.00% | - | 4.40倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
市場注目の銘柄
チャート関連のコラム